Point: Cesium-131: Ready for prime time

Brachytherapy

Volumn 8, Issue 1, 2009, Pages 1-3

  Bice, William S ^a  

^a Foundation for Medical Physics Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CESIUM 131; IODINE 125; PALLADIUM 103; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG IMPLANTATION; HUMAN; PAIN; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION SAFETY; RECTUM DISEASE; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE;

BRACHYTHERAPY; CESIUM RADIOISOTOPES; DIFFUSION OF INNOVATION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 58149517189     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2008.11.002     Document Type: Article

References (30)

1. Lauer L. Personal communication, 2008. Richland, WA.
2. Armpilia C.I., Dale R.G., Coles I.P., Merrick G., True L., et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys 55 (2003) 378-385
3. Brenner D.J., Martinez A.A., Edmundson G.R., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
4. D'Souza W.D., and Thames H.D. Is the alpha/beta ratio for prostate cancer low?. Int J Radiat Oncol Biol Phys 51 (2001) 1-3
5. Duchesne G.M., and Peters L.J. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 44 (1999) 747-748
6. King C.R., and Fowler J.F. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51 (2001) 213-214
7. Yaes R.J. Late normal tissue injury from permanent interstitial implants. Int J Radiat Oncol Biol Phys 49 (2001) 1163-1169
8. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 22 (1995) 209-234
9. Rivard M.J., Butler W.M., DeWerd L.A., et al. Supplement to the 2004 update of the AAPM Task Group No. 43 Report. Med Phys 34 (2007) 2187-2205
10. Williamson J., Coursey B.M., DeWerd L.A., et al. Dosimetric prerequisites for routine clinical use of new low energy photon interstitial brachytherapy sources. Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee. Ad Hoc Subcommittee of the Radiation Therapy Committee. Med Phys 25 (1998) 2269-2270
11. Chen Z., Bongiorni P., and Nath R. Dose rate constant of a cesium-131 interstitial brachytherapy seed measured by thermoluminescent dosimetry and gamma-ray spectrometry. Med Phys 32 (2005) 3279-3285
12. Murphy M.K., Piper R.K., Greenwood L.R., et al. Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Med Phys 31 (2004) 1529-1538
13. Rivard M.J. Brachytherapy dosimetry parameters calculated for a 131Cs source. Med Phys 34 (2007) 754-762
14. Wang J., and Zhang H. Dosimetric characterization of model Cs-1 Rev2 cesium-131 brachytherapy source in water phantoms and human tissues with MCNP5 Monte Carlo simulation. Med Phys 35 (2008) 1571-1579
15. 131Cs: a consensus report from the Cesium Advisory Group. Brachytherapy 7 (2008) 290-296
16. Unknown. Yale Prostate Cancer Seeding Study shows palladium-103 superior to older therapy: fewer side effects, could lead to better treatment outcomes. PSA Rising Magazine (1999)
17. Wallner K., Merrick G., True L., et al. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 8 (2002) 67-73
18. Lee W.R. In regards to Wallner, et al: (125)I versus (103)PD for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial (I 2003;57:1297-1303). Int J Radiat Oncol Biol Phys 59 (2004) 319 author reply 319-320
19. Brenner DJ. Estimation of optimal Cs-131 boost dose for combined external-beam/boost treatment for prostate cancer; 2005.
20. Dale R.G. Comparison of the radiobiological effects of Cs-131 implants with those associated with I-125 and Pd-103 implants (2004), IsoRay Medical, Richland, WA
21. Williamson J.F., Cousey B.M., DeWerd L.A., et al. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. Med Phys 27 (2000) 634-642
22. Peschel R.E., Chen Z., Roberts K., et al. Long-term complications with prostate implants: iodine-125 vs. palladium-103. Radiat Oncol Investig 7 (1999) 278-288
23. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
24. Cha C.M., Potters L., Ashley R., et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 45 (1999) 391-395
25. Peschel R.E., Coldberg J.W., Chen Z., et al. Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications. Cancer J 10 (2004) 170-174
26. Sharkey J., Chovnickn S.D., Behar R.J., et al. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. Urology 51 (1998) 796-803
27. Wallner K., Merrick G., True L., et al. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
28. Wallner K., Merrick G., True L., et al. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol 75 (2005) 307-310
29. Lee W.R., Moughan J., Owen J.B., et al. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer 98 (2003) 1987-1994
30. Prestidge B.R., et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 40 (1998) 461-465